Opendata, web and dolomites

AutArt

Clinical validation of the AutArt rheumatoid arthritis diagnostic device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AutArt project word cloud

Explore the words cloud of the AutArt project. It provides you a very rough idea of what is the project "AutArt" about.

cartilage    toolkit    progression    action    30    line    modifying    ray    drugs    ineffective    regular    sustainability    software    eur    282    consists    detection    image    clinical    device    autart    social    causing    market    first    bone    economic    automatically    union    diagnostic    health    heijde    sharp    competitors    2009    decreased    follow    2020    destroy    chronic    healthcare    pharmaceutical    patients    selling    scheduled    dynamically    der    deformity    treatment    establishment    diagnoses    rheumatoid    mds    sale    contributes    intensive    lining    joints    van    provides    billion    group    precision    treatments    2014    validation    medical    causes    sold    millions    service    inflammation    monitoring    agents    regulation    precise    arthritis    moment    50    autoimmune    disease    scoring    points    became    people    considerably    biologic    permanently    comparability    rising    feasibility    objectivity    sas    estimate    successful    serious    million    act    diagnosis    ten    ra    share    15    25    disabled    companies    time    evaluation   

Project "AutArt" data sheet

The following table provides information about the project.

Coordinator
BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: SZABOLCSKA MIHALY UTCA 1 FSZT 3
city: BUDAPEST
postcode: 1114
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.bifarma.hu
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) coordinator 50˙000.00

Map

 Project objective

The AutArt diagnostic toolkit is a medical device that automatically diagnoses the progression of Rheumatoid Arthritis (RA) on an X-Ray image by using the Sharp/van der Heijde scoring system. This Phase 1 feasibility study will support the clinical validation of the device in Phase 2 that we estimate will cost between 1.5-2 million EUR; with the first market sale scheduled within 2 years, sold SAS (Software as a Service). RA is a chronic autoimmune disease that causes inflammation of the lining of the joints, which can destroy cartilage and bone, causing deformity of the joints. RA is a serious economic and social problem, 20-30% of early RA patients become permanently work disabled during the first 2-3 years of the disease and more than 50% of patients with RA became work disabled during the first ten years of the disease. Classical disease-modifying drugs are ineffective in about 10-15% of the cases, furthermore, biologic agents may also be ineffective. Early detection, regular clinical monitoring and comparable, objective evaluation is essential for successful treatment. The AutArt medical device is the result of 2 years of intensive R&D and at the moment there are no serious competitors in the market, so this is the time to act for a dynamically rising market share in the RA diagnostic market. The target group consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity, comparability and precision. In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be decreased considerably with the AutArt medical device. This project is in line with the 282/2014/EU regulation on the establishment of a third Programme for the Union’s action in the field of health (2014-2020) because it contributes to the sustainability of the healthcare system and provides millions of people with better treatment through more precise diagnosis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AUTART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More